tradingkey.logo

Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo’S Canadian Portfolio

ReutersJun 5, 2025 11:16 AM

Knight Therapeutics Inc GUD.TO:

  • KNIGHT THERAPEUTICS AND SUMITOMO PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENTS TO COMMERCIALIZE SUMITOMO’S CANADIAN PORTFOLIO

  • KNIGHT THERAPEUTICS INC - DEAL INCLUDES UPFRONT AMOUNT OF C$25.4 MILLION

  • KNIGHT THERAPEUTICS: MAY PAY FUTURE CONTINGENT PAYMENTS OF UP TO C$15.75 MILLION

  • KNIGHT THERAPEUTICS INC - EXPECTED TO PAY C$7 MILLION FOR INVENTORY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI